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ABSTRACT 
 
Objectives  We have undertaken a clinic-based survey of neuromyelitis 
optica spectrum disorders (NMOSD) in Australia and New Zealand in order 
to establish incidence and prevalence across the region and in populations 
of differing ancestry. 
Background  NMOSD is a recently defined demyelinating disease of the 
central nervous system. The incidence and prevalence of NMOSD in 
Australia and New Zealand has not been established. 
Methods  Centres managing patients with demyelinating disease of the 
CNS across Australia and New Zealand reported patients with clinical and 
laboratory features that were suspicious for NMOSD. Testing for AQP4 
antibodies was undertaken in all suspected cases. From this group, cases 
were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for 
NMOSD. A capture-recapture methodology was used to estimate incidence 
and prevalence, based on additional laboratory identified cases. 
Results  NMOSD was confirmed in 81/170 (48%) cases referred. Capture-
recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 
0.35 – 0.39) per million per year and a prevalence estimate for NMOSD of 
0.70 (95% CI 0.61 – 0.78) per 100,000. NMOSD was 3-times more common 
in the Asian population (1.57 [95% CI 1.15 – 1.98] per 100,000) compared 
with the remainder of the population (0.57 [95% CI 0.50 – 0.65] per 
100,000). The latitudinal gradient evident in multiple sclerosis was not seen 
in NMOSD. 
Conclusions  NMOSD incidence and prevalence in Australia and New 
Zealand are comparable with figures from other populations of largely 
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European ancestry. We found NMOSD to be more common in the 
population with Asian ancestry. 
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INTRODUCTION 
 
Neuromyelitis optica spectrum disorders (NMOSD) are an antibody-
mediated autoimmune disease of the central nervous system (CNS) in 
which the primary target is aquaporin 4 (AQP4), a water channel found in 
high density on the end-feet of astrocytes, particularly those in close 
proximity to the blood brain barrier.1 Difficulties in identifying NMOSD and 
distinguishing it from multiple sclerosis were dramatically reduced by the 
discovery of AQP4 antibodies in 2004.2 Since the identification of these 
seemingly specific and pathogenic antibodies,3 the phenotype of this 
autoimmune astrocytopathy has broadened.4 It has been noted that the 
relative frequency of NMOSD is higher in populations of Asian ancestry 
(50% of CNS demyelinating disease)5 compared with in populations of 
predominantly European ancestry (1% of CNS demyelinating disease).6 
 
A number of studies have attempted to estimate the population prevalence 
and incidence of NMOSD in various parts of the world. However, many of 
these studies have been based on AQP4 antibody positivity from laboratory 
testing. As a result few population-based clinical surveys of the frequency of 
NMOSD exist.7 Australia and New Zealand have a population of 27 – 28 
million people with predominantly European ancestry. Both have 
comprehensive healthcare systems, with a network of adult and paediatric 
neurologists who have a subspecialty interest in CNS demyelinating 
disease. We have undertaken a clinic-based survey of NMOSD, using a 
clinical method of case ascertainment with the aim of estimating the 
ANZ NMOSD Epidemiology  ANZ NMO Collaboration 6 
 
 
population incidence and prevalence of NMOSD. As secondary aims we 
wished to explore the geographical and ethnic distribution of NMOSD. 
 
METHODS 
 
Case Ascertainment 
 
Possible cases of NMOSD were identified using a network of 36 adult and 
paediatric neurologists at 23 clinics specialising in demyelinating diseases 
of the central nervous system (ICD-10 G35-G37) across Australia and New 
Zealand. These centres covered every capital and major city of each state 
or region, as well as several smaller urban centres. Australia and New 
Zealand have comprehensive state health care systems in which most 
patients with demyelinating diseases of the central nervous system are 
cared for in specialist clinics. Participating neurologists and paediatric 
neurologists were requested to notify the coordinating centre in Queensland 
of patients with features identified in earlier diagnostic criteria8 that are 
highly suggestive of NMOSD. To be included as a suspected NMOSD case 
one of the following ‘high risk’ clinical and laboratory features had to be met 
1) optic neuritis that was either severe with poor recovery (residual visual 
acuity in better eye worse or equal to 6/36), bilateral (simultaneous or 
sequential within 3 months) or recurrent (more than 2 attacks) as the sole 
clinical manifestation of demyelinating disease, 2) severe transverse 
myelitis with a central cord syndrome (symmetrical, motor, sensory and 
bladder involvement) and poor recovery (residual EDSS greater than 5.0) or 
a longitudinally extensive lesion of the spinal cord spanning 3 or more 
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vertebral segments on magnetic resonance imaging (MRI) or 3) 
demyelinating disease clinically confined to the optic nerve and spinal cord 
with at least one of the following: normal or atypical MRI of the brain (fewer 
than 2 periventricular lesions9), negative oligoclonal bands in cerebrospinal 
fluid, raised CSF protein or a CSF pleocytosis (more than 10 cells per µl). 
Cases were excluded if no serum sample was supplied and clinical criteria 
for NMOSD were not met, insufficient clinical data were supplied, inclusion 
criteria for suspected NMOSD were not met, an alternate diagnosis became 
apparent or subject declined to provide written informed consent. The period 
of data collection was from 1 January 2011 to 31 December 2013. Informed, 
written consent was obtained for all cases and institutional human research 
ethics committee approval was obtained for all participating sites. 
 
To facilitate a capture-recapture methodology, the four laboratories in 
Australia that offer routine AQP4-Ab testing provided details of positive 
cases detected in their laboratories for the same time period. Details on 
these cases included date of birth, initials, age, gender, state/country and 
ethnicity [Asian or Other]) thereby ensuring the avoidance of double 
counting and facilitating a whole of population analysis by age, gender, 
region and ethnicity. 
 
Case Definition 
 
Demographic details (age, gender and ethnicity), relapse history, findings on 
clinical examination and results of CSF analysis and any prior AQP4-Ab 
testing were collected using a standard questionnaire in all cases. Serum 
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samples were obtained and tested for AQP4-Ab using immunofluorescence 
staining techniques on mouse, rat or monkey brain tissue and rat or mouse 
kidney sections. A subset of samples was also tested using an ELISA kit, as 
well as M23 AQP4 transfected HEK cells in a fixed cell assay 
(Euroimmun™, Germany) and a live cell based assay.10 MRI of brain, orbits 
and spinal cord were obtained where available. Cases were defined as 
having NMOSD (ICD-10 G36) and included in the analysis if they met the 
2015 Wingerchuk criteria.11  
 
Estimation of incidence and prevalence 
 
Crude incidence rates with 95% confidence intervals were calculated, using 
the normal approximation to the binomial distribution, from the mean 
number of cases with disease onset (date of first symptoms) occurring from 
2009 to 2012 inclusive. The inevitable lag between symptom onset and 
clinical assessment means that new cases would typically be identified and 
referred to the study sometime after the onset of their symptoms. Therefore 
incident cases for the collection year 2013 were not included. Crude point 
prevalence rates were calculated for the prevalence date of 1 July 2013. To 
be included in the prevalence estimate cases were required to have disease 
onset on or before 1 July 2013 and be alive on this date. Gender and age-
adjustment was performed using the WHO Standard World Population 
Distribution for 2005 to 2025.12 
 
The Lincoln-Peterson capture-recapture method13 was used to adjust 
prevalence and incidence rates in light of laboratory identified cases that 
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had been missed in the clinical survey. Standard methods were used to 
estimate a 95% confidence interval for this adjusted prevalence rate.14 All 
analyses were conducted on a state and country basis, to allow for regional 
variations in referral practice, before being combined. Prevalence rates 
were also estimated for cases with Asian ancestry separately using the 
same capture-recapture methodology. The definition of Asian ancestry was 
self-determined but indicated to include those whose genealogical ancestry 
arose in the continent of Asia. 
 
Population estimates for Australian states and New Zealand were obtained 
from the Australian Bureau of Statistics and Statistics New Zealand 
websites.15 16 For incidence, population estimates for 2011 were used (the 
mid-point of the study years). For prevalence, population estimates for 2013 
were used (the year of the prevalence date). Latitudinal variation in 
prevalence was analysed using the latitude of the centre of population for 
each region.15-17 The relationship between latitude and prevalence was 
explored using a regression analysis weighted by the reciprocal variance 
using Stata® v14.0 software (StataCorp, Texas, USA). 
 
RESULTS 
 
Incidence and prevalence of NMOSD 
 
A total of 177 cases of suspected NMOSD were referred to the study centre. 
Of these 7/177 (4%) were excluded (no serum sample received in 1, 
inclusion criteria not met in 2, incomplete clinical data in 3 and alternative 
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diagnosis in 1). The one case excluded because of no serum sample being 
supplied did not meet the clinical criteria for NMOSD. Clinical information, 
results of testing for AQP4 antibodies and MR imaging results were 
available for all of the remaining 170 suspected cases of NMOSD permitting 
application of the 2015 Wingerchuk criteria. A cell-based assay was used in 
79/177 (46%) of suspected cases, immunofluorescence tissue assay was 
performed in all. NMOSD was confirmed in 81/170 (48%) cases and 73/81 
(90%) were seropositive for AQP4 antibodies. The laboratory survey 
identified 117 AQP4 antibody positive cases of which 70 were not identified 
in the clinical survey, giving a total of 151 cases of NMOSD. There were 34 
incident cases over the period 2010 to 2012, giving a crude incidence of 
0.33 (95% CI 0.11 – 0.55) per million per year. Two cases died prior to the 
prevalence date and 2 cases had disease onset after the prevalence date 
leaving 147 prevalent cases and giving a crude point prevalence of 0.53 
(95% CI 0.45 – 0.62) per 100,000. Standardising to the World Health 
Organisation 2005-2025 world population gave a gender and age-adjusted 
prevalence figure of 0.44 (95% CI 0.36 – 0.52) per 100,000. There were 
126/147 (86%) female cases, giving a female to male ratio of 6:1. The 
frequency distribution by age is shown in Figure 1. The peak prevalence 
age range for women was 40 – 59 years and for men was 60 – 69 years. 
 
Capture-recapture analysis and lifetime risk of NMOSD 
 
There were 47/73 (64%) cases from the clinical survey that were recaptured 
in the laboratory survey. For the capture-recapture analysis we have 
extrapolated the total number of seronegative cases assuming the same 
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proportion of missed cases as seen with the seropositive cases. An 
additional 8 ‘seronegative’ cases were added according to the observed 
regional distribution. Capture-recapture gave an adjusted incidence 
estimate of 0.37 (95% CI 0.35 – 0.39) per million per year and gave an 
estimated total number of NMOSD cases of 193 and prevalence of 0.70 
(95% CI 0.66 – 0.74) per 100,000. The results for prevalence estimates by 
state, ancestry and overall are shown in Table 1. The prevalence of 
NMOSD in the population of Australia and New Zealand with Asian ancestry 
was 1.57 (95% CI 1.15 – 1.98) per 100,000 compared with 0.57 (95% CI 
0.50 – 0.65) per 100,000 in the remainder of the population. The lifetime risk 
of developing NMOSD was calculated using the cumulative age of onset for
  
Table 1. Crude and adjusted NMOSD prevalence estimates by region, ancestry and overall 
 
Subpopulation NMOSD Cases Population Latitude Crude Prevalenceb Adj Prevalencec 
  Clinical Only Clinical & Laboratory Laboratory Onlya Total   (º South) (per 100,000)  (per 100,000) 
Region 
         
QLD/NT 
 
2 12 26 (2) 40 4,898,100 25.0954 0.82 (0.56 – 1.08) 0.95 (0.78 – 1.12) 
WA 
 
1 1 4 6 2,517,200 31.5906 0.24 (0.05 – 0.43) 0.40 (0.00 – 0.89) 
NSW/ACT 
 
11 17 27 (2) 55 7,791,100 33.5302 0.68 (0.50 – 0.86) 0.93 (0.71 – 1.15) 
SA 
 
2 3 2 7 1,670,800 34.8474 0.37 (0.09 – 0.64) 0.44 (0.24 – 0.63) 
VIC/TAS 
 
3 10 13 (2) 26 6,250,600 38.0848 0.43 (0.24 – 0.62) 0.56 (0.42 – 0.71) 
NZ 
 
6 9 6 (2) 21 4,442,100 38.1507 0.38 (0.23 – 0.53) 0.47 (0.37 – 0.58) 
Ancestry 
 
        
Asian 
 
6 12 22 40 3,259,047 
 
1.23 (0.85 –1.61) 1.57 (1.15 – 1.98) 
Other 
 
18 41 56 (8) 115 24,410,853 
 
0.44 (0.36 – 0.52) 0.57 (0.50 – 0.65) 
Total 25 52 78 155 27,669,900    0.65 (0.58 – 0.73)  0.70 (0.61 – 0.78) 
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QLD = Queensland; NT = Northern Territory; WA = Western Australia; NSW = New South Wales; ACT = Australian Capital Territory; 
SA = South Australia; VIC = Victoria; TAS = Tasmania; NZ = New Zealand; Adj = Adjusted 
a Figures in parentheses indicate estimated numbers of missed seronegative cases added to the estimate 
b Excludes estimated numbers of missed seronegative cases, figures in parentheses indicate 95% confidence interval 
c Adjusted using Lincoln-Peterson capture-recapture methodology, figures in parentheses indicate 95% confidence interval 
 
  
 the clinical survey cases (data not shown) as 1.26 (95% CI 1.13 – 1.39) per 
100,000. 
 
 
Latitudinal variation in NMOSD prevalence 
 
The prevalence estimates by region are illustrated in Figure 2 and show no 
increase in prevalence with increasing latitude. In fact there is a reverse 
relationship which is statistically significant (p=0.044). Exclusion of cases 
and state populations with Asian ancestry did not significantly alter this 
finding. 
 
DISCUSSION 
 
This is the first incidence and prevalence survey of NMOSD in the Oceania 
region. We have utilised a clinical survey method combined with a 
laboratory-based capture-recapture methodology to estimate the incidence 
and prevalence of NMOSD in Australia and New Zealand and have results 
that are similar to those previously recorded for both European and Asian 
populations. The estimates of incidence and prevalence reported here are 
at the lower end of previous study results (Table 2). There are two studies 
with significantly higher estimates of prevalence18 19 and one of these also 
has a significantly higher estimate of incidence.19 These studies included 
methodologies likely to have a high pick up rate for cases of NMOSD 
through multiple healthcare sources and national databases19 or systematic 
serological testing of all possible cases.18 Relatively small sample sizes  
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Table 2. Incidence and prevalence of NMOSD in populations of Caucasian ancestry 
 
Studyref Population Incidence (95% CI) Prevalence (95% CI) 
  (per million per year) (per 100,000) 
Cabrera-Gomez et al 200920 Cuba 0.44 (0.3 – 0.62) 0.43 (0.29 – 0.61) 
Asgari et al 201119 Denmark 4 (3 – 5.4) 4.41 (3.1 – 5.7) 
Cossburn et al 201221 Wales 
  
1.96 (1.22 – 2.97) 
Jacob et al 201322 Merseyside 0.8 (0.3 – 1.6) 0.72 (0.31 – 1.42)  
Etemadifar et al 201423 Iran 
  
1.95 (1.62 – 2.23) 
Kashopazha et al 201524 Iran 
  
0.8 (0.54 – 1.06) 
Flanagan et al 201618a  Olmstead 0.7 (0 – 2.1) 3.9 (0.8 – 7.1) 
Present Study ANZ 0.37 (0.36 – 0.38) 0.7 (0.66 – 0.74) 
 
Results are as presented in original papers 
ANZ = Australia and New Zealand 
a Age and gender-adjusted figures 
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means that these higher prevalence figures could represent statistical 
random variation (the number of affected cases in the recent USA study 
was only 6).18 Conversely, it is likely the results presented here are an 
underestimate. There are a number of limitations with the present study. 
Firstly, only a proportion of our suspected cases had testing for AQP4 
antibodies with a cell-based assay. Secondly, we have not tested every 
patient with demyelinating disease of the central nervous system for AQP4 
antibodies. These limitations are however, only likely to have a relatively 
small impact on the overall prevalence. A third and more significant 
limitation is that only currently or recently active cases who have been seen 
in clinics or undergone AQP4 antibody testing will have been identified. 
Against this is the fact that the age-specific rates of NMOSD in the present 
series was very consistent for the higher age groups. Finally, we have used 
the 2015 Wingerchuk criteria,11 which are more stringent with regards to 
seronegative NMOSD. Confirmation of seronegative cases was also 
constrained by the availability of relevant MR imaging having ever been 
performed. There is certainly also a potential for the referral of these cases 
to have been reduced compared to seropositive cases, despite the 
clinically-based mechanism of referral for the initial capture. 
 
The overall estimated number of cases of NMOSD (193) represents less 
than 1% of the 26,600 people with multiple sclerosis estimated to be living in 
Australia25 and New Zealand.26 This is a similar proportion to that seen in 
other European populations. The increased frequency of NMOSD in women 
is consistent with previous studies. In a survey using the same methodology 
across a defined geographical region we have demonstrated a higher 
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prevalence of NMOSD in people with Asian ancestry (3-fold increase 
compared with the remaining population of predominantly European 
ancestry). 
 
The present data do not support a latitudinal gradient in NMOSD as 
compared with MS for this region.27 28 In fact the data suggest a possible 
weak inverse relationship, with prevalence increasing at lower latitudes. 
This does not appear to be explained by regional variations in the proportion 
with Asian ancestry in each region as the trend remained when these 
populations were removed. Another possible explanation could be ease of 
access to serological testing, as the two states with the highest prevalence 
of NMOSD have the two laboratories with the highest through put of AQP4 
antibody testing. The proportions of new cases identified through the 
laboratory survey certainly suggest that this may have been a factor with the 
two most distant regions (South Australia/Northern Territory) and New 
Zealand having the lowest proportions of cases detected through the 
laboratory survey. We have demonstrated an increased frequency of 
NMOSD in women compared to men consistent with previous studies 
(Table 3). 
 
In conclusion, the Australia and New Zealand region has incidence and 
prevalence estimates for NMOSD which are within the ranges seen in other 
populations around the world, with the possible exception of populations 
with African ancestry.18 The prevalence of NMOSD is higher in people with 
Asian ancestry compared with the remaining predominantly European 
ancestry population of Australia and New Zealand and NMOSD does not 
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share the latitudinal gradient seen with MS across this region. It therefore 
seems likely that the epidemiology of NMOSD is different to MS and that 
susceptibility factors thought to be important in MS (e.g. vitamin D and 
sunlight) may not play a significant role in NMOSD. 
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Table 3. Female:Male ratios in NMOSD cohorts 
 
Authorref Population Inclusion Criteria N Female (%) Male (%) Ratio (F:M) 
Asian 
      
Nagaishi et al 201129 Japan AQP4-Ab positive 583 533 (91) 50 (9) 10.7:1 
Barhate et al 201430 India 2006 Wingerchuk 44 39 (89) 5 (11) 7.8:1 
Pandit & Kundapur 201431 India 2006/2007 Wingerchuk 11 6 (55) 5 (45) 1.2:1 
Yin et al 201532 China 2006 Wingerchuk plusa 108 92 (85) 16 (15) 5.8:1 
Black 
      
Flanagan et al 201618 US/Martinique AQP4-Ab positive 45 40 (89) 5 (11) 8:1 
Daoudi & Bouzar 201633 Algeria 2015 Wingerchuk 8 6 (75) 2 (25) 3:1 
Caucasian 
      
Rivera et al 200834 Mexico 1999 Wingerchuk 34 24 (71) 10 (29) 2.4:1 
Cabrera-Gomez et al 200920 Cuba 1999 Wingerchuk 58 51 (88) 7 (12) 7.3:1 
Asgari et al 201119 Denmark 2006 Wingerchuk 42 31 (74) 11 (26) 2.8:1 
Collongues et al 201135 France 2006 Wingerchuk 155 108 (70) 47 (30) 2.3:1 
Cossburn et al 201221 Wales 2007 Wingerchuk 14 12 (86) 2 (14) 6:1 
Aboul-Enein et al 201336 Austria AQP4-Ab positive 71 62 (87) 9 (13) 6.9:1 
Jacob et al 201322 England 2006 Wingerchuk 8 7 (88) 1 (13) 7:1 
Etemadifar et al 201423 Iran 2006 Wingerchuk 95 66 (69) 29 (31) 2.3:1 
Kashipazha et al 201524 Iran 2006 Wingerchuk plusb 36 30 (83) 6 (17) 5:1 
Chitnis et al 201637 USc 2006 Wingerchuk plusd 38 26 (68) 12 (32) 2.2:1 
Sepulveda et al 201638 Spain 2006 Wingerchuk 181 157 (87) 24 (13) 6.5:1 
Kleiter et al 201639 Germany 2006 Wingerchuk plusa 186 152 (82) 34 (18) 4.5:1 
Present Study ANZ 2015 Wingerchuk 147 126 (86) 21 (14) 6:1 
Combined     1864 1568 (84) 296 (16) 5.3:1 
 
a additional criteria included AQP4-Ab positive high risk syndromes 
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FIGURE LEGENDS 
 
Figure 1 
 
Gender and age distribution of NMOSD in Australia and New Zealand. 
 
Figure 2 
 
Latitudinal variation in prevalence of NMOSD across Australia and New 
Zealand. 
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